These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38604819)

  • 1. Chronic myeloid leukaemia: Biology and therapy.
    Wang Y; Liang ZJ; Gale RP; Liao HZ; Ma J; Gong TJ; Shao YQ; Liang Y
    Blood Rev; 2024 May; 65():101196. PubMed ID: 38604819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
    Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Kockerols C; Valk PJM; Janssen JJWM; Hogenbirk P; Cornelissen JJ; Saussele S; Spiess B; Perusini MA; Kim D; Westerweel PE
    Eur J Haematol; 2024 Nov; 113(5):606-613. PubMed ID: 38994654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
    Dulucq S; Mahon FX
    Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
    Caldemeyer L; Akard LP
    Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
    Saugues S; Lambert C; Daguenet E; Roth-Guepin G; Huguet F; Cony-Makhoul P; Ansah HJ; Escoffre-Barbe M; Turhan A; Rousselot P; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
    Haematologica; 2024 Sep; 109(9):2893-2907. PubMed ID: 38695126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.
    Clark RE
    Curr Hematol Malig Rep; 2019 Dec; 14(6):507-514. PubMed ID: 31701369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 10. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
    Haznedaroğlu İC; Kuzu I; İlhan O
    Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
    Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J; Rea D; Lipton JH
    Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
    Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
    Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
    Elsayed AG; Srivastava R; Jamil MO
    Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
    Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
    Laneuville P
    Curr Treat Options Oncol; 2018 Mar; 19(3):15. PubMed ID: 29520446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-free remission in patients with chronic myeloid leukaemia.
    Ross DM; Hughes TP
    Nat Rev Clin Oncol; 2020 Aug; 17(8):493-503. PubMed ID: 32377005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.